Brendan Eckelman
Net worth: 8 M $ as of 2024-05-30
Profile
Brendan P.
Eckelman is the founder of Inhibrx LP, which was founded in 2010.
He held the title of Vice President-Scientific Operations from 2010 to 2014.
He is also the founder of Inhibrx, Inc., which was founded in 2010.
He held the title of Chief Scientific Officer from 2021 to 2024.
Currently, Dr. Eckelman is the Chief Scientific Officer & Executive VP at Inhibrx Biosciences, Inc. since 2024.
In the past, he worked as a Research Investigator at Novartis Institute for Functional Genomics, Inc. Dr. Eckelman received his undergraduate and graduate degrees from the University of California San Diego and his doctorate degree from UC San Diego School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
inf% | 2024-05-29 | 513,888 ( inf% ) | 8 M $ | 2024-05-30 |
Brendan Eckelman active positions
| Companies | Position | Start |
|---|
Former positions of Brendan Eckelman
| Companies | Position | End |
|---|---|---|
| INHIBRX, INC. | Founder | 2024-05-29 |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Inhibrx LP
 Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Founder | - |
Training of Brendan Eckelman
| University of California San Diego | Graduate Degree |
| UC San Diego School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| INHIBRX, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Inhibrx LP
Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Health Technology |
- Stock Market
- Insiders
- Brendan Eckelman
